MX2022003408A - Usos del complejo de metabolito antagonista del receptor de angiotensina ii e inhibidor de nep en el tratamiento de la insuficiencia cardiaca. - Google Patents

Usos del complejo de metabolito antagonista del receptor de angiotensina ii e inhibidor de nep en el tratamiento de la insuficiencia cardiaca.

Info

Publication number
MX2022003408A
MX2022003408A MX2022003408A MX2022003408A MX2022003408A MX 2022003408 A MX2022003408 A MX 2022003408A MX 2022003408 A MX2022003408 A MX 2022003408A MX 2022003408 A MX2022003408 A MX 2022003408A MX 2022003408 A MX2022003408 A MX 2022003408A
Authority
MX
Mexico
Prior art keywords
complex
heart failure
angiotensin
receptor antagonist
nep inhibitor
Prior art date
Application number
MX2022003408A
Other languages
English (en)
Inventor
Jingchao Sun
Xiaolong Jing
Original Assignee
Shenzhen Salubris Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Salubris Pharm Co Ltd filed Critical Shenzhen Salubris Pharm Co Ltd
Publication of MX2022003408A publication Critical patent/MX2022003408A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Los usos de un complejo de un metabolito antagonista del receptor de angiotensina II y un inhibidor de NEP para la insuficiencia cardíaca, se relacionan específicamente los usos del complejo en la preparación de un medicamento para su uso en la insuficiencia cardíaca con fracción de expulsión reducida (HFrEF).
MX2022003408A 2019-09-20 2020-09-18 Usos del complejo de metabolito antagonista del receptor de angiotensina ii e inhibidor de nep en el tratamiento de la insuficiencia cardiaca. MX2022003408A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910890853 2019-09-20
CN202010901984 2020-09-01
PCT/CN2020/116023 WO2021052441A1 (zh) 2019-09-20 2020-09-18 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途

Publications (1)

Publication Number Publication Date
MX2022003408A true MX2022003408A (es) 2022-07-12

Family

ID=74883393

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003408A MX2022003408A (es) 2019-09-20 2020-09-18 Usos del complejo de metabolito antagonista del receptor de angiotensina ii e inhibidor de nep en el tratamiento de la insuficiencia cardiaca.

Country Status (13)

Country Link
US (1) US20220395491A1 (es)
EP (1) EP4032532A4 (es)
JP (1) JP7316449B2 (es)
KR (1) KR20220012317A (es)
CN (2) CN113286585B (es)
AU (1) AU2020348813A1 (es)
CA (1) CA3151788A1 (es)
CO (1) CO2022004910A2 (es)
EC (1) ECSP22031078A (es)
MX (1) MX2022003408A (es)
TW (1) TWI809313B (es)
WO (1) WO2021052441A1 (es)
ZA (1) ZA202204370B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7316449B2 (ja) * 2019-09-20 2023-07-27 シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド 心不全治療におけるアンジオテンシンｉｉ受容体アンタゴニスト代謝産物とｎｅｐ阻害剤との複合体の使用
TW202228677A (zh) * 2020-08-17 2022-08-01 大陸商深圳信立泰藥業股份有限公司 血管收縮素ｉｉ受體拮抗劑代謝產物與ｎｅｐ抑制劑的複合物用於心臟衰竭的應用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004203284A1 (en) * 1998-11-06 2004-08-12 G.D. Searle & Co. Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
US20060014829A1 (en) * 2004-07-16 2006-01-19 Nitromed, Inc. Methods for reducing hospitalizations related to heart failure
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
AR089954A1 (es) * 2012-02-15 2014-10-01 Theravance Inc Forma cristalina del ester 5-metil-2-oxo-[1,3]dioxol-4-ilmetilico del acido (2s,4r)-5-bifenil-4-il-2-hidroximetil-2-metil-4-[(1h-[1,2,3]triazol-4-carbonil)amino]pentanoico
WO2015028941A1 (en) * 2013-08-26 2015-03-05 Novartis Ag New use
CN105503760A (zh) * 2014-10-10 2016-04-20 上海翰森生物医药科技有限公司 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
CN106138041A (zh) * 2015-04-15 2016-11-23 苏州朗科生物技术有限公司 一种双重作用的氯沙坦复合物
CN106146472A (zh) * 2015-04-15 2016-11-23 苏州朗科生物技术有限公司 一种双重作用的阿利沙坦复合物
HUE062195T2 (hu) * 2015-05-11 2023-10-28 Novartis Ag Szakubitril - valzartán adagolási rend szívelégtelenség kezelésére
WO2017006254A1 (en) * 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
CN105669581B (zh) * 2015-11-09 2017-03-22 成都苑东生物制药股份有限公司 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物
AU2017209250B2 (en) * 2016-01-20 2021-07-29 Shenzhen Salubris Pharmaceuticals Co. Ltd Angiotensin II receptor antagonist metabolite and NEP inhibitor composite, and preparation method thereof
AU2017229466C1 (en) * 2016-03-08 2021-02-11 Theravance Biopharma R&D Ip, Llc Crystalline(2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-YL)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
CN106177960B (zh) * 2016-08-01 2019-01-08 珠海赛隆药业股份有限公司（长沙）医药研发中心 血管紧张素受体拮抗剂和脑啡肽酶抑制剂的复合物及其用途
CN106924241A (zh) * 2017-04-28 2017-07-07 广州医科大学 川陈皮素在预防或治疗心衰药物中的应用
CA3138080A1 (en) * 2019-05-19 2020-11-26 Jean-Francois TAMBY Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl) n-(isoxazol-3-yl)piperidine-1-carboxamid
US20220226285A1 (en) * 2019-05-30 2022-07-21 Shenzhen Salubris Pharmaceuticals Co., Ltd. Treatment Method Using A Complex of Angiotensin II Receptor Antagonist Metabolite and NEP Inhibitor
JP7316449B2 (ja) * 2019-09-20 2023-07-27 シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド 心不全治療におけるアンジオテンシンｉｉ受容体アンタゴニスト代謝産物とｎｅｐ阻害剤との複合体の使用
TW202228677A (zh) * 2020-08-17 2022-08-01 大陸商深圳信立泰藥業股份有限公司 血管收縮素ｉｉ受體拮抗劑代謝產物與ｎｅｐ抑制劑的複合物用於心臟衰竭的應用

Also Published As

Publication number Publication date
CN113286585A (zh) 2021-08-20
ECSP22031078A (es) 2022-08-31
US20220395491A1 (en) 2022-12-15
TWI809313B (zh) 2023-07-21
CN115487175A (zh) 2022-12-20
ZA202204370B (en) 2022-11-30
EP4032532A4 (en) 2023-10-04
AU2020348813A1 (en) 2022-04-14
JP2022545904A (ja) 2022-11-01
EP4032532A1 (en) 2022-07-27
CO2022004910A2 (es) 2022-05-31
CA3151788A1 (en) 2021-03-25
CN115487175B (zh) 2024-05-14
WO2021052441A1 (zh) 2021-03-25
CN113286585B (zh) 2022-11-08
JP7316449B2 (ja) 2023-07-27
KR20220012317A (ko) 2022-02-03
TW202114652A (zh) 2021-04-16

Similar Documents

Publication Publication Date Title
EP3952779A4 (en) SYSTEMS, PROCESSES AND WORKFLOW FOR CONCURRENT PROCEEDINGS
MX2022003408A (es) Usos del complejo de metabolito antagonista del receptor de angiotensina ii e inhibidor de nep en el tratamiento de la insuficiencia cardiaca.
WO2015110923A3 (en) Btk inhibitor for the treatment of chronic lymphocytic and small lymphocytic leukemia
CL2012003053A1 (es) Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad.
SG11201808607SA (en) Medicine obtained by combining fxr agonist and arb
MX2020000190A (es) Métodos para tratar la insuficiencia cardíaca con activadores de sarcómero cardíaco.
CY1125273T1 (el) Ανταγωνιστης υποδοχεα glp-1 για χρηση στη θεραπεια συγγενους υπερινσουλινισμου
WO2016110806A3 (en) Dosage regimen for madcam antagonists
MX2017000366A (es) Terapia de combinacion para el cancer.
MX2018012700A (es) Semaglutida en afecciones cardiovasculares.
MX2017005884A (es) Metodos para el tratamiento de la erc, utilizando predictores de la retencion de liquidos.
PH12017502099A1 (en) Methods for diagnosing and assessing treatment for cushing's syndrome
EP3980017A4 (en) Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality
AR107963A1 (es) Forma cristalina de sales de 1-(5-(2,4-difluorfenil) -1-((3-fluorfenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina
EP3918561A4 (en) SYSTEMS AND PROCEDURES FOR GENERATION, MANAGEMENT AND ANALYSIS OF USER EXPERIENCE TESTS
GB202018729D0 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor
WO2013156546A3 (en) Endoprosthesis leakage analysis
EP3906932A3 (en) Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
WO2017046228A3 (en) Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
HUP1800441A1 (hu) Aktív szék, elsõsorban irodai használatra
MX2022001396A (es) Metodos para tratar trastornos asociados con niveles elevados de anticuerpos que interactuan con el receptor de nmda.
ES2530425A1 (es) Procedimiento, sistema y dispositivo para determinar si se realiza el traspaso entre frecuencias en redes de telecomunicaciones
WO2021011874A8 (en) Ghrh antagonists for use in a method of treating sarcoidosis
MX2022006891A (es) Terapia combinada con liv1-adc y antagonista de pd-1.
EP4047142A4 (en) MEASURING DEVICE AND CONSTRUCTION MACHINE